{"id":"W1978824248","doi":"10.1038/jid.2011.304","title":"A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis","year":2011,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Abbott Laboratories","keywords":"Placebo; Medicine; Adverse effect; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Gastroenterology; Surgery; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002067425,0.001941322,0.004486265,0.0004229366,0.0005777976,0.00142107,0.00124096,0.001648191,0.006428465],"category_scores_gemma":[0.001607262,0.0008315968,0.001743165,0.0004923121,0.001604177,0.001331673,0.0004412495,0.004399948,0.00109483],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007723693,"about_ca_system_score_gemma":0.001207543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001451877,"about_ca_topic_score_gemma":0.002628643,"domain_scores_codex":[0.9993838,0.0002957903,0.00002807349,0.0001117345,0.00004506612,0.0001355306],"domain_scores_gemma":[0.999153,0.0002475976,0.0001425324,0.00008101485,0.00005497618,0.0003207202],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9823017,0.004622732,0.0002256398,0.0003999701,0.0007556579,0.00003085536,0.00003298262,0.0002326777,0.002455786,0.000106553,0.0007976784,0.008037644],"study_design_scores_gemma":[0.9699523,0.0284535,0.0005502972,0.00001488085,0.0002486447,0.00001869536,0.00001281959,0.0001647381,0.0001671751,0.00009303861,0.0003163728,0.000007568542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768161,0.008704871,0.001764767,0.001585978,0.001588323,0.004849386,0.00131984,0.0003230646,0.003047768],"genre_scores_gemma":[0.9819852,0.003965456,0.002020088,0.001891708,0.0006830388,0.004206273,0.001089523,0.00005479196,0.004103951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006428465,"threshold_uncertainty_score":0.0215053,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03313375104487552,"score_gpt":0.267880182342678,"score_spread":0.2347464312978025,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}